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Sir,  
We write in response to the letter published in the BDJ by Kanatas and 
Brotherton “Erosive lichen planus; BDJ 2014 216:545”. Erosive and ulcerative lesions 
of oral lichen planus (OLP) can be persistent and painful (1); therapy is warranted 
when patients have painful disease that may adversely impact upon quality of life, 
but effective management of OLP can be challenging (2). The authors presented 
their recent preliminary experience with betamethasone valerate 0.05% cream 
(Betnovate®), which, they report, seems beneficial in controlling painful symptoms 
and worthy further investigations.  
This is perhaps not unexpected, as a wide spectrum of corticosteroid formulations 
including mouthwashes, creams, ointments, sprays and intralesional injections have 
been reported in the treatment of symptomatic OLP (3-5). Nevertheless there 
remains a lack of well designed clinical trials in this field, with a relatively recent 
systematic review indicating that there is little robust evidence for the efficacy of any 
single treatment for the management of erosive OLP (6).  
Although we are grateful to Dr Kanatas and Brotherton for their preliminary report on 
betamethasone therapy, we would like to highlight that comprehensive management 
of OLP can be a significantly more complex matter, as it encompasses a number of 
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issues that go beyond the far too simple question of which topical corticosteroid is 
most effective in controlling painful symptoms of OLP.  
For example, we would like to draw readers' attention to the medicolegal 
responsibility that falls on healthcare professionals when prescribing, dispensing and 
administering an agent outwith its licensed indication. It is important that clinicians 
inform patients of the off-label use of these agents and detail possible adverse side 
effects (7). Certainly patients should be carefully reviewed for such events.  
Perhaps the most important aspect of OLP management remains its malignant 
potential and the associated increased risk of oral cancer development (8). A recent 
systematic review suggests that the overall prevalence of oral cancer in the OLP 
population (regardless of type, patient characteristics or mode of management of the 
disease) may be up to 3.5% (9). As the risk of oral squamous cell carcinoma in OLP 
is often unpredictable, the long-term monitoring of patients with OLP is a crucial 
issue so to attempt to identify and diagnose early dysplastic and malignant changes 
(10). Again there remains little robust evidence but perhaps long-term surveillance 
warrants shared care between the primary and secondary health care providers. 
Undoubtedly, despite the best efforts of attending clinicians, some patients with OLP 
will develop oral mucosal dysplasia or malignancy, although early diagnosis can 
lessen the need for complex therapy and may ultimately improve the prognosis of 
affected individuals. 
Any patient with possible OLP should be initially referred to specialists to ensure that 
(i) the diagnosis is formally confirmed, (ii) appropriate treatment is provided and (iii) 
adequate and evidence-based information is given. Simply telling a patient that they 
are likely to have OLP is often unhelpful and sometimes they can become alarmed 
after surfing the World Wide Web. Patients’ perspective and expectation are also 
important, as conversations regarding the chronic nature of the disease and 
associated increased risk of cancer may sometimes become difficult.  
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